Short answer
Organogenesis Holdings Inc. (ORGO) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal Q2 2026 results covered quarter ended June 30, 2026.
Organogenesis Holdings Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal Q2 2026 results covered quarter ended June 30, 2026
- Earnings details provided in Exhibit 99.1 press release
- Disclosure furnished under Regulation FD, limiting Section 18 Exchange Act liability
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $42.8M, down 58%, with Advanced Wound Care falling 61% to $36.1M
- Gross margin collapsed to 45% from 73%, while net loss widened to $96.3M from $9.4M
- Adjusted EBITDA loss reached $34.4M, reflecting severe operating deleverage despite SG&A declining 27%
- Cash, cash equivalents and restricted cash fell to $46.8M from $94.3M, with no outstanding debt obligations
- FY2026 revenue outlook cut to $179M-$215M, implying a 62%-68% decline versus 2025 revenue of $564.2M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Organogenesis Holdings Inc. 8-K filings
Get the next ORGO 8-K as it lands
Follow ORGO for push alerts, or ask the research agent what this filing means.